<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388061</url>
  </required_header>
  <id_info>
    <org_study_id>NTA1401</org_study_id>
    <nct_id>NCT02388061</nct_id>
  </id_info>
  <brief_title>Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke</brief_title>
  <acronym>EXTEND-IA TNK</acronym>
  <official_title>Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuroscience Trials Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Florey Institute of Neuroscience and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuroscience Trials Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting to the emergency department with acute ischemic stroke, who are are
      eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be
      assessed for major vessel occlusion to determine their eligibility for randomization into the
      trial. If the patient gives informed consent they will be randomised 50:50 using central
      computerised allocation to intravenous alteplase or tenecteplase before all participants
      undergo intra-arterial clot retrieval. The trial is prospective, randomised, open-label,
      blinded endpoint (PROBE) design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2015</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">October 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with substantial angiographic reperfusion (mTICI) score of 2b/3 (restoration of blood flow to &gt;50% of the affected arterial territory) or absence of retrievable thrombus at initial angiogram.</measure>
    <time_frame>Initial angiogram (day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥8 point reduction in NIHSS or reaching 0-1 at 3 days (favourable clinical response) adjusted for baseline NIHSS and age.</measure>
    <time_frame>Initial angiogram (day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) at 3 months</measure>
    <time_frame>3 months post stroke</time_frame>
    <description>ordinal analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS 0-1 or no change from baseline at 3 months</measure>
    <time_frame>3 months post stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS 0-2 or no change from baseline at 3 months</measure>
    <time_frame>3 months post stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage (SICH)</measure>
    <time_frame>within 36 hours post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to any cause</measure>
    <time_frame>Up to 3 months post stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with angiographic reperfusion adjusted for hyperdense clot length on non-contrast CT and time from thrombolysis to initial angiogram</measure>
    <time_frame>Up to 24 hours post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intravenous tenecteplase (TNK)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous tissue plasminogen activator (tPA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <arm_group_label>Intravenous tenecteplase (TNK)</arm_group_label>
    <other_name>TNK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator</intervention_name>
    <arm_group_label>Intravenous tissue plasminogen activator (tPA)</arm_group_label>
    <other_name>Alteplase</other_name>
    <other_name>tPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients presenting with acute ischemic stroke eligible using standard criteria to
             receive IV thrombolysis within 4.5 hours of stroke onset

          2. Patient's age is ≥18 years

          3. Intra-arterial clot retrieval treatment can commence (arterial puncture) within 6
             hours of stroke onset.

          4. Arterial occlusion on CTA or MRA of the ICA, M1, M2 or basilar artery.

        Exclusion Criteria:

          1. Intracranial hemorrhage (ICH) identified by CT or MRI

          2. Rapidly improving symptoms at the discretion of the investigator

          3. Pre-stroke mRS score of ≥ 4 (indicating previous disability)

          4. Hypodensity in &gt;1/3 MCA territory or equivalent proportion of basilar artery territory
             on non-contrast CT

          5. Contra indication to imaging with contrast agents

          6. Any terminal illness such that patient would not be expected to survive more than 1
             year

          7. Any condition that, in the judgment of the investigator could impose hazards to the
             patient if study therapy is initiated or affect the participation of the patient in
             the study.

          8. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Heath</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

